A phase II study of XXXX in advanced @entity957 (a Gynecologic Oncology Group Study).

@entity1 @entity137 @entity3003 @entity957 @entity900 @entity344 @entity2359
The Gynecologic Oncology Group conducted a Phase II trial of @entity3003 in @entity1 with measurable advanced @entity957 . No prior therapy with cytotoxic drugs was permitted in @entity1 entered into this study. @entity1 entered were GOG performance status 2 or better. @entity3003 400 mg/m2 (340 mg/m2 in @entity1 who had had prior pelvic radiotherapy with subsequent escalation to 400 mg/m2 if bone marrow tolerance was good) was administered as a 15-minute IV infusion. Treatments were repeated every four weeks until disease progressed or until @entity137 prohibited further therapy. Thirty-nine evaluable @entity1 were treated. Two complete and nine partial responses were observed (response rate 28.2%). No @entity2359 and only mild reversible nephrotoxicity was seen. @entity344 was severe in three @entity1 (7.7%). Dose limiting @entity137 was myelosuppression. @entity3003 is active against @entity957 and appears to be less nephrotoxic, @entity2359 , and nauseogenic than @entity900 . Randomized studies of this drug against @entity900 are indicated to determine the role of @entity3003 in the therapy of @entity957 .
